EQS-News: Sangui BioTech International Inc.: Significant increase in sales in the first three quarters of the year - Further reduction of the operating loss
Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656.
- Hamburg, February 13, 2023: In the first six months of fiscal year 2023 (to 30/06/2023) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,656.
- In the same period of the previous year the comparable revenue amounted to USD 40,732.
- As a result of the above factors, the six-month operating loss decreased USD 19,556 to USD 43,689.
- Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group.